Clinical trial
0804 GCC: MAGE-A3/HPV 16 Vaccine for Squamous Cell Carcinoma of the Head and…
NCT00257738 · University of Maryland, Baltimore, Other · Completed
Key facts
| NCT number | NCT00257738 |
|---|---|
| Title | 0804 GCC: MAGE-A3/HPV 16 Vaccine for Squamous Cell Carcinoma of the Head and Neck |
| Official title | A Phase 1 Open Label, Dose Escalation Study to Evaluate the Effect of Four Doses of MAGE-A3/HPV 16 Trojan Peptides 0001 and 0002 Administered Subcutaneously in Combination With Montanide and GM-CSF on Immunological Response, Safety, Tolerability, and Preliminary Efficacy in Patients With Squamous… |
| Lead sponsor | University of Maryland, Baltimore, Other |
| Collaborators | National Institute of Dental and Craniofacial Research (NIDCR) NIH |
| Status | Completed |
| Phase | Phase 1 |
| Study type | Interventional |
| Conditions | Squamous Cell Carcinoma of the Head and Neck |
| Intervention type | Biological |
| Interventions | MAGE-A3, HPV-16 vaccine |
| Enrollment | 17 |
| Start date | Nov 1, 2005 |
| Primary completion | Oct 1, 2012 |
| Completion | Oct 1, 2012 |
| First posted | Nov 23, 2005 |
| Last update posted | Oct 17, 2019 |
| Countries | United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: